Work

PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.6_suppl.272

Authors: Michael J. Morris, Nicholas J. Vogelzang, A. Oliver Sartor, Alison A. Armour, Richard Adam Messmann, Michael Groaning, Adam Robarts, Anthony W. Tolcher, Michael S. Gordon, Hani M. Babiker, Phillip Kuo, Megan Kearney, Adam Jendrisak, Yipeng Wang, Mark Andrew Landers, Daniel Peter Petrylak

Institutions: Memorial Sloan Kettering Cancer Center, Comprehensive Cancer Centers of Nevada, Tulane University, Endocyte (United States), ProNAi Therapeutics (United States), South Texas Accelerated Research Therapeutics, HonorHealth, Pinnacle Oncology Hematology, University of Arizona Cancer Center, University of Arizona, Epic Sciences (United States), Yale University

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2791226314

Cites:

Cited by: 2

Related to: 10